Navigation Links
Insulet Corporation Announces Pricing of $75 Million of Convertible Senior Notes
Date:6/10/2008

BEDFORD, Mass., June 10 /PRNewswire-FirstCall/ -- Insulet Corporation (the "Company") (Nasdaq: PODD) announced today that it has priced a private offering of $75 million in aggregate principal amount of its convertible senior notes due 2013 (the "notes") to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended. The Company has granted the initial purchasers an option to purchase up to an additional $10 million in aggregate principal amount of notes solely to cover over-allotments, if any.

The notes will pay interest semi-annually at a rate of 5.375% per annum and mature on June 15, 2013. The notes will have an initial conversion rate of 46.8467 shares of the Company's common stock per $1,000 principal amount of the notes, representing an initial conversion price of approximately $21.35 per share of common stock. Subject to customary closing conditions, the Company expects to close the offering on June 16, 2008.

The Company will use the net proceeds from the offering to repay and terminate its outstanding term loan and for general corporate purposes.

This notice does not constitute an offer to sell or a solicitation of an offer to buy securities. Any offers of the notes will be made only by means of a private offering memorandum. The notes and any common stock of the Company issuable upon conversion of the notes have not been registered under the Securities Act of 1933, as amended, or the securities laws of any other jurisdiction and may not be offered or sold absent registration or an applicable exemption from registration requirements.

This press release contains forward-looking statements concerning the Company's expectations, anticipations, intentions, beliefs o
'/>"/>

SOURCE Insulet Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Insulet Awarded National Accreditation for Excellence by Community Health Accreditation Program
2. Insulet Corporation Announces Pricing of Secondary Public Offering
3. Insulet Corporation to Report Third Quarter 2007 Financial Results on Wednesday, November 14th
4. Insulet Corporation to Present at the JPMorgan Healthcare Conference on January 8, 2008
5. Insulet Corporation and DexCom Announce Development Agreement
6. Insulet Corporation to Present at the Seventh Annual JMP Securities Research Conference on May 20, 2008
7. Insulet Corporation to Present at the Canaccord Adams Diabetes & Obesity Conference on June 6, 2008
8. Insulet Announces Development Agreement for the First Non-Diabetes Drug Delivery Application for the OmniPod System
9. Insulet Corporation Announces Private Offering of $65 Million of Convertible Senior Notes
10. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2009)... Interleukin Genetics, Inc. (NYSE Amex: ILI ) announced ... New York,s Department of Health for the Company to ... determines predisposition to severe periodontal disease in individuals. ... in the U.S. However, through its Clinical Laboratory ... reliability of results of laboratory tests, including genetic tests, ...
(Date:12/7/2009)... WARREN, Mich., Dec. 7 Intravenous fluids, ... imaging...does this match the picture of a typical ... southeast Michigan suffering with cancer, this description sadly ... for sledding and the time to sit on ... happy holiday moments. Testing and treatments come first, ...
(Date:12/7/2009)... of the board of directors for PerfectServe, a clinical communications ... , ... Knoxville, Tenn. (PRWEB) ... executive chairman of the board of directors for PerfectServe ... hospitals and practices nationwide. , , , , ,Barduson is ...
(Date:12/7/2009)... Thomson Reuters today announced the release of Micromedex ... information system. ,, Pharmacists, nurses, and physicians in ... Micromedex, which provides evidence-based information on drugs, disease ... education. ,, The new version gives clinicians the ... leader over the last 30 years -- along ...
(Date:12/7/2009)... Zogenix, Inc. ("Zogenix"), a privately held ... a $35 million second tranche of a Series ... round was increased from $51 million, previously announced ... million investment was made by Chicago Growth Partners, ... Board of Directors by Dr. Arda Minocherhomjee. ...
Breaking Medicine News(10 mins):Health News:Interleukin Genetics Receives Approval To Sell its PST(R) Periodontal Disease Genetic Test in New York 2Health News:Interleukin Genetics Receives Approval To Sell its PST(R) Periodontal Disease Genetic Test in New York 3Health News:Help Young Cancer Patients Enjoy Christmas This Season 2Health News:Gene Barduson Named Chairman of PerfectServe Board of Directors 2Health News:Thomson Reuters Releases Micromedex 2.0 2Health News:Thomson Reuters Releases Micromedex 2.0 3Health News:Zogenix Increases Series B Preferred Stock Financing to $71 Million, Raising $35 Million in Second Tranche 2
... believed. And its death dance continues unabated in the region. ... the unfortunate people. ,Africa has increased the ... to 1.3 million last year, but a lack of medical ... the report released Thursday by Medecins Sans Frontieres. ...
... more human-like mouse model of cancer they say will aid ... of laboratory drug testing. ,The study was ... A. DePinho, Lynda Chin at the Dana-Farber Cancer Institute. ... oncogene into a mouse embryo. , "You plug ...
... US researcher has discovered a cocktail of enzymes that converts ... can be fed into a fuel cell to run an ... engine. ,The method hinges on a mixture ... and yeast, but never together in nature. ...
... cells from human umbilical cord blood to make insulin. ... by allowing people to grow their own insulin-producing cells for ... conducted by a team of researchers led by Dr. Randall ... ,As part of the study, researchers tested adult ...
... by researchers at Mayo Clinic College of Medicine in ... stop smoking by referring them to tobacco-use telephone ... general dental practitioners to provide either brief counseling regarding ... a tobacco-use quitline for patients who were smoked cigarettes. ...
... in Orissa's tribal dominated Koraput district, while five have ... health officials said Friday. ,Bisu Sisa, ... Padiguda village under Semliguda block in Koraput, nearly 500 ... consuming cattle meat. ,K.H. Reddy, chief district ...
Other Medicine News:Health News:Shortage of Doctors and Nurses Affects AIDS Treatment in Africa 2Health News:Shortage of Doctors and Nurses Affects AIDS Treatment in Africa 3Health News:New Mouse Model to Aid in Cancer-causing Genes Hunt 2Health News:Researchers Discover Starch Cocktail Fuel for green Car 2
(Date:12/7/2009)... -- Merieux Alliance, the Merieux,family holding company, ... to take on,the historic name of Institut ... Paris,Alain Merieux reviewed the important role played ... public health challenges including infectious diseases, cancer,personalized ... and the management teams, he outlined the ...
(Date:12/4/2009)... simple, inexpensive computer tool that measures volume changes in ... up by a CT scanner can rule out non-cancerous ... diagnose true cancers with fewer, less expensive and less ... new diagnostic guidelines are described in a paper published ...
(Date:12/4/2009)... 4 Amber Pharmacy announced today that it received ... (ACHC) for specialized pharmacy services. For nearly 15 years, ... services to meet the unique needs of specialized conditions. ... services to transplant programs. They work with over 170 ...
Breaking Medicine Technology:Merieux Alliance Becomes Institut Merieux 2Merieux Alliance Becomes Institut Merieux 3Merieux Alliance Becomes Institut Merieux 4European Lung Cancer Screening Trial Demonstrates New Inexpensive Strategy for Improving Accuracy of Diagnosis 2Amber Pharmacy Earns Accreditation From ACHC 2Sono Tek Announces Second Quarter Results 5398 1Sono Tek Announces Second Quarter Results 5398 2Sono Tek Announces Second Quarter Results 5398 3Iowas Largest Health System Launches First in the Nation Statewide Electronic Prescribing 5396 1Iowas Largest Health System Launches First in the Nation Statewide Electronic Prescribing 5396 2Iowas Largest Health System Launches First in the Nation Statewide Electronic Prescribing 5396 3Iowas Largest Health System Launches First in the Nation Statewide Electronic Prescribing 5396 4Iowas Largest Health System Launches First in the Nation Statewide Electronic Prescribing 5396 5Iowas Largest Health System Launches First in the Nation Statewide Electronic Prescribing 5396 6Iowas Largest Health System Launches First in the Nation Statewide Electronic Prescribing 5396 7Dendreon Announces Election of Ian Clark and Pedro Granadillo to Board of Directors 5393 1Dendreon Announces Election of Ian Clark and Pedro Granadillo to Board of Directors 5393 2
... 21 Today at the,World Congress of Cardiology ... Fibrillation Management" chaired by John Camm,Professor of Clinical ... of the newly announced ATHENA clinical trial,results, as ... Atrial,fibrillation, the most common form of cardiac arrhythmia., ...
... second half of 2008 --,-- Presentation at the Seventh Annual ... of corporate update scheduled during Ardea,s ... a.m. PT --, SAN DIEGO, May 20 Ardea ... presented on the Company,s,lead mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, ...
Other Medicine Technology:ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 2ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 3ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 4ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 5ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 6Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis 2Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis 3Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis 4
... A necessary addition to ... the Reichert Trial Frame ... and smooth controls for ... robust design, high-quality materials, ...
... The Ultramatic Rx Master is ... years of reliable service and ... that measurably improve procedures. It ... need and want most, including ...
The Maverick Over-The-Wire balloon catheter delivers a new level of performance to meet the changing demands of interventional cardiology....
... Illumination is provided by a cool-running, ... light only what you need to see ... best of all they are maintenance free ... light bulb. Every Phoroptor comes with a ...
Medicine Products: